---
document_datetime: 2025-12-02 04:49:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/takhzyro.html
document_name: takhzyro.html
version: success
processing_time: 0.1273568
conversion_datetime: 2025-12-27 21:03:18.192311
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Takhzyro

[RSS](/en/individual-human-medicine.xml/67160)

##### Authorised

This medicine is authorised for use in the European Union

lanadelumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Takhzyro](#news-on)
- [More information on Takhzyro](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Takhzyro is a medicine used to prevent attacks of hereditary angioedema in patients aged 2 years and over.

Patients with angioedema have rapid swelling under the skin in areas such as the face, throat, arms and legs. Attacks of hereditary angioedema can be life threatening when the swelling around the throat presses against the airway.

Hereditary angioedema is rare, and Takhzyro was designated an 'orphan medicine' (a medicine used in rare diseases) on 9 October 2015. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3151551](https://www.ema.europa.eu/medicines/human/orphan-designations/eu3151551) .

Takhzyro contains the active substance lanadelumab.

Expand section

Collapse section

## How is Takhzyro used?

Takhzyro is given as an injection under the skin, preferably in the abdomen (belly), thighs or upper arms. The recommended dose and frequency depends on the patient's age and bodyweight. At the beginning of treatment the dose is usually given every 2 weeks, which the doctor can reduce to once every 4 weeks if the patient remains free of attacks with the two-weekly dose.

Caregivers or patients aged 12 years and above may inject the medicine themselves after they have been properly trained.

Takhzyro can only be obtained with a prescription and should be started under supervision of a doctor experienced in managing hereditary angioedema.

For more information about using Takhzyro, see the package leaflet or contact your doctor or pharmacist.

## How does Takhzyro work?

Patients with hereditary angioedema have high levels of a substance called 'bradykinin', which causes blood vessels to widen and leak fluid into the surrounding tissue leading to the swelling attacks seen in angioedema.

The active substance in Takhzyro, lanadelumab, works by attaching to and blocking an enzyme in the blood called 'kallikrein', which has several functions, including increasing levels of bradykinin. By blocking the actions of kallikrein, lanadelumab helps to prevent the swelling and related symptoms of angioedema.

## What benefits of Takhzyro have been shown in studies?

Takhzyro was found to be effective in reducing the number of angioedema attacks in a main study in 126 adults and children above 12 years of age with hereditary angioedema.

Patients experienced on average 0.3 attacks per month when given Takhzyro injections every 2 weeks and 0.5 attacks when given injections every 4 weeks. This compared with 2 attacks per month for patients on placebo (a dummy treatment).

An additional study was carried out in 21 children with hereditary angioedema aged between 2 and 12 years. Treatment with Takhzyro reduced the number of angioedema attacks from on average 1.84 attacks per month to 0.08 attacks after one year of treatment.

## What are the risks associated with Takhzyro?

For the full list of side effects and restrictions with Takhzyro, see the package leaflet.

The most common side effects with Takhzyro (which may affect more than 1 patient in 10) include reactions at the site of injection including erythema (redness), bruising and pain.

## Why is Takhzyro authorised in the EU?

Takhzyro is effective in preventing angioedema attacks and the fact that it only needs to be given every 2 or 4 weeks was considered an advantage over existing treatments. Overall, the safety profile was considered acceptable.

The European Medicines Agency therefore decided that Takhzyro's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Takhzyro?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Takhzyro have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Takhzyro are continuously monitored. Side effects reported with Takhzyro are carefully evaluated and any necessary action taken to protect patients.

## Other information about Takhzyro

Takhzyro received a marketing authorisation valid throughout the EU on 22 November 2018.

This overview was last updated in 10-2023.

Takhzyro : EPAR - Medicine overview

Reference Number: EMA/734573/2018

English (EN) (117.22 KB - PDF)

**First published:** 17/12/2018

**Last updated:** 22/11/2023

[View](/en/documents/overview/takhzyro-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-184)

български (BG) (139.85 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/bg/documents/overview/takhzyro-epar-medicine-overview_bg.pdf)

español (ES) (117.17 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/es/documents/overview/takhzyro-epar-medicine-overview_es.pdf)

čeština (CS) (138.63 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/cs/documents/overview/takhzyro-epar-medicine-overview_cs.pdf)

dansk (DA) (116.66 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/da/documents/overview/takhzyro-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.12 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/de/documents/overview/takhzyro-epar-medicine-overview_de.pdf)

eesti keel (ET) (114.48 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/et/documents/overview/takhzyro-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.16 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/el/documents/overview/takhzyro-epar-medicine-overview_el.pdf)

français (FR) (118.79 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/fr/documents/overview/takhzyro-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.45 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/hr/documents/overview/takhzyro-epar-medicine-overview_hr.pdf)

italiano (IT) (116.47 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/it/documents/overview/takhzyro-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.21 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/lv/documents/overview/takhzyro-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.64 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/lt/documents/overview/takhzyro-epar-medicine-overview_lt.pdf)

magyar (HU) (137.45 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/hu/documents/overview/takhzyro-epar-medicine-overview_hu.pdf)

Malti (MT) (140.55 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/mt/documents/overview/takhzyro-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.46 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/nl/documents/overview/takhzyro-epar-medicine-overview_nl.pdf)

polski (PL) (139.65 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/pl/documents/overview/takhzyro-epar-medicine-overview_pl.pdf)

português (PT) (118.03 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/pt/documents/overview/takhzyro-epar-medicine-overview_pt.pdf)

română (RO) (138.26 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/ro/documents/overview/takhzyro-epar-medicine-overview_ro.pdf)

slovenčina (SK) (159.12 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/sk/documents/overview/takhzyro-epar-medicine-overview_sk.pdf)

slovenščina (SL) (136.81 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/sl/documents/overview/takhzyro-epar-medicine-overview_sl.pdf)

Suomi (FI) (115 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/fi/documents/overview/takhzyro-epar-medicine-overview_fi.pdf)

svenska (SV) (116.45 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

22/11/2023

[View](/sv/documents/overview/takhzyro-epar-medicine-overview_sv.pdf)

Takhzyro : EPAR - Risk management plan

English (EN) (610.56 KB - PDF)

**First published:** 22/11/2023

**Last updated:** 02/06/2025

[View](/en/documents/rmp/takhzyro-epar-risk-management-plan_en.pdf)

## Product information

Takhzyro : EPAR - Product information

English (EN) (2.29 MB - PDF)

**First published:** 17/12/2018

**Last updated:** 02/06/2025

[View](/en/documents/product-information/takhzyro-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-261)

български (BG) (2.97 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/bg/documents/product-information/takhzyro-epar-product-information_bg.pdf)

español (ES) (2.19 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/es/documents/product-information/takhzyro-epar-product-information_es.pdf)

čeština (CS) (2.97 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/cs/documents/product-information/takhzyro-epar-product-information_cs.pdf)

dansk (DA) (2.22 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/da/documents/product-information/takhzyro-epar-product-information_da.pdf)

Deutsch (DE) (2.35 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/de/documents/product-information/takhzyro-epar-product-information_de.pdf)

eesti keel (ET) (2.26 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/et/documents/product-information/takhzyro-epar-product-information_et.pdf)

ελληνικά (EL) (3.07 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/el/documents/product-information/takhzyro-epar-product-information_el.pdf)

français (FR) (2.88 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/fr/documents/product-information/takhzyro-epar-product-information_fr.pdf)

hrvatski (HR) (2.81 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/hr/documents/product-information/takhzyro-epar-product-information_hr.pdf)

íslenska (IS) (2.2 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/is/documents/product-information/takhzyro-epar-product-information_is.pdf)

italiano (IT) (2.28 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/it/documents/product-information/takhzyro-epar-product-information_it.pdf)

latviešu valoda (LV) (3 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/lv/documents/product-information/takhzyro-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.88 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/lt/documents/product-information/takhzyro-epar-product-information_lt.pdf)

magyar (HU) (2.69 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/hu/documents/product-information/takhzyro-epar-product-information_hu.pdf)

Malti (MT) (2.81 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/mt/documents/product-information/takhzyro-epar-product-information_mt.pdf)

Nederlands (NL) (2.3 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/nl/documents/product-information/takhzyro-epar-product-information_nl.pdf)

norsk (NO) (2.27 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/no/documents/product-information/takhzyro-epar-product-information_no.pdf)

polski (PL) (2.41 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/pl/documents/product-information/takhzyro-epar-product-information_pl.pdf)

português (PT) (2.72 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/pt/documents/product-information/takhzyro-epar-product-information_pt.pdf)

română (RO) (2.88 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/ro/documents/product-information/takhzyro-epar-product-information_ro.pdf)

slovenčina (SK) (2.84 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/sk/documents/product-information/takhzyro-epar-product-information_sk.pdf)

slovenščina (SL) (2.59 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/sl/documents/product-information/takhzyro-epar-product-information_sl.pdf)

Suomi (FI) (2.25 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/fi/documents/product-information/takhzyro-epar-product-information_fi.pdf)

svenska (SV) (2.27 MB - PDF)

**First published:**

17/12/2018

**Last updated:**

02/06/2025

[View](/sv/documents/product-information/takhzyro-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0040 25/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Takhzyro : EPAR - All authorised presentations

English (EN) (103.41 KB - PDF)

**First published:** 17/12/2018

**Last updated:** 26/03/2025

[View](/en/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-782)

български (BG) (103.26 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/bg/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_bg.pdf)

español (ES) (63.46 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/es/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_es.pdf)

čeština (CS) (117.46 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/cs/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (64.87 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/da/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (66.25 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/de/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (63.08 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/et/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (99.99 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/el/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_el.pdf)

français (FR) (65.11 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/fr/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (120.13 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/hr/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (64.47 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/is/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_is.pdf)

italiano (IT) (63.67 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/it/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (128.23 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/lv/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (111.16 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/lt/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (103.14 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/hu/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (103.33 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/mt/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (67.37 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/nl/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (65.83 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/no/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_no.pdf)

polski (PL) (101.26 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/pl/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_pl.pdf)

português (PT) (65.64 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/pt/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_pt.pdf)

română (RO) (99.56 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/ro/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (115.15 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/sk/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (89.8 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/sl/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (63.18 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/fi/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (65.06 KB - PDF)

**First published:**

17/12/2018

**Last updated:**

26/03/2025

[View](/sv/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Takhzyro Active substance lanadelumab International non-proprietary name (INN) or common name lanadelumab Therapeutic area (MeSH) Angioedemas, Hereditary Anatomical therapeutic chemical (ATC) code B06AC05

### Pharmacotherapeutic group

Other hematological agents

### Therapeutic indication

Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.

## Authorisation details

EMA product number EMEA/H/C/004806

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Takeda Pharmaceuticals International AG Ireland Branch

Block 2 Miesian Plaza

Opinion adopted 18/10/2018 Marketing authorisation issued 22/11/2018 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Takhzyro : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (249.51 KB - PDF)

**First published:** 01/10/2019

**Last updated:** 02/06/2025

[View](/en/documents/procedural-steps-after/takhzyro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Takhzyro-PAM-0000285505 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2276197

English (EN) (372.13 KB - PDF)

**First published:** 02/10/2025

[View](/en/documents/variation-report/takhzyro-pam-0000285505-epar-assessment-report_en.pdf)

Takhzyro-PAM-0000258207 : EPAR - Assessment report

Reference Number: EMADOC-1700519818-1976152

English (EN) (382.16 KB - PDF)

**First published:** 15/09/2025

**Last updated:** 01/10/2025

[View](/en/documents/variation-report/takhzyro-pam-0000258207-epar-assessment-report_en.pdf)

Takhzyro-H-C-004806-P46-010 : EPAR - Assessment report

Adopted

Reference Number: EMA/550456/2024

English (EN) (341.4 KB - PDF)

**First published:** 18/12/2024

[View](/en/documents/variation-report/takhzyro-h-c-004806-p46-010-epar-assessment-report_en.pdf)

Takhzyro : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMA/CHMP/424426/2023

English (EN) (123.76 KB - PDF)

**First published:** 15/10/2024

[View](/en/documents/pip-compliance/takhzyro-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

Takhzyro-H-C-4806-P46-009 : EPAR - Assessment report

Adopted

Reference Number: EMA/420652/2024

English (EN) (251.63 KB - PDF)

**First published:** 30/09/2024

[View](/en/documents/variation-report/takhzyro-h-c-4806-p46-009-epar-assessment-report_en.pdf)

Takhzyro-H-C-4806-P46-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/153700/2024

English (EN) (458.48 KB - PDF)

**First published:** 18/04/2024

[View](/en/documents/variation-report/takhzyro-h-c-4806-p46-008-epar-assessment-report_en.pdf)

Takhzyro-H-C-4806-P46-007 : EPAR - Assessment report

Adopted

Reference Number: EMA/153698/2024

English (EN) (403.9 KB - PDF)

**First published:** 11/04/2024

[View](/en/documents/variation-report/takhzyro-h-c-4806-p46-007-epar-assessment-report_en.pdf)

Takhzyro-H-C-4806-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/8343/2024

English (EN) (595.89 KB - PDF)

**First published:** 10/01/2024

[View](/en/documents/variation-report/takhzyro-h-c-4806-p46-006-epar-assessment-report_en.pdf)

Takhzyro-H-C-4806-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/548309/2023

English (EN) (258.78 KB - PDF)

**First published:** 20/12/2023

[View](/en/documents/variation-report/takhzyro-h-c-4806-p46-005-epar-assessment-report_en.pdf)

Takhzyro-H-C-4806-X-0034-G : EPAR - Assessment report - Extension

Adopted

Reference Number: EMA/440820/2023

English (EN) (2.14 MB - PDF)

**First published:** 22/11/2023

[View](/en/documents/variation-report/takhzyro-h-c-4806-x-0034-g-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Takhzyro (X-0032-G)

Adopted

Reference Number: EMA/CHMP/400511/2023

English (EN) (130.05 KB - PDF)

**First published:** 15/09/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-takhzyro-x-0032-g_en.pdf)

Takhzyro-H-C-4806-P46-004 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/804964/2022

English (EN) (424.42 KB - PDF)

**First published:** 13/12/2022

[View](/en/documents/variation-report/takhzyro-h-c-4806-p46-004-epar-assessment-report_en.pdf)

Takhzyro-H-C-4806-P46-001.1 : EPAR - Assessment report

Adopted

English (EN) (780.02 KB - PDF)

**First published:** 16/12/2021

[View](/en/documents/variation-report/takhzyro-h-c-4806-p46-0011-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Takhzyro : EPAR - Public assessment report

Adopted

Reference Number: EMA/794314/2018

English (EN) (3.85 MB - PDF)

**First published:** 17/12/2018

[View](/en/documents/assessment-report/takhzyro-epar-public-assessment-report_en.pdf)

Takhzyro: Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/809232/2018

English (EN) (693.21 KB - PDF)

**First published:** 17/12/2018

[View](/en/documents/orphan-maintenance-report/takhzyro-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Takhzyro

Adopted

Reference Number: EMA/700432/2018

English (EN) (71.66 KB - PDF)

**First published:** 19/10/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-takhzyro_en.pdf)

#### News on Takhzyro

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018) 19/10/2018

[New medicine for hereditary angioedema, a rare disease causing swelling beneath the skin](/en/news/new-medicine-hereditary-angioedema-rare-disease-causing-swelling-beneath-skin) 19/10/2018

#### More information on Takhzyro

- [EU/3/15/1551 - orphan designation for treatment of hereditary angioedema](/en/medicines/human/orphan-designations/eu-3-15-1551)
- [EMEA-001864-PIP01-15-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001864-pip01-15-m07)
- [EMEA-001864-PIP02-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001864-pip02-19)
- [EMEA-001864-PIP03-19-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001864-pip03-19-m01)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/10/2025

## Share this page

[Back to top](#main-content)